Literature DB >> 21896259

Risk factors for glaucoma: what do they really mean?

Anthea Worley1, Karen Grimmer-Somers.   

Abstract

Glaucoma is an insidious eye disease, potentially putting 4% of older Australians at risk of blindness, unless detected sufficiently early for initiation of effective treatment. This paper reports on the strengths of evidence and glaucoma risk factors that can be identified by primary health care providers from a patient's history. A comprehensive search of peer-reviewed databases identified relevant secondary evidence published between 2002 and 2007. Risk factors that could be determined from a patient's history were identified. A novel glaucoma risk factor reference guide was constructed according to evidence strength and level of concern regarding risk of developing glaucoma. The evidence is strong and consistent regarding the risk of developing glaucoma, and elevated intraocular pressure, advancing age, non-Caucasian ethnicity and family history of glaucoma. There is moderate evidence of association with glaucoma, and migraine, eye injury, myopia and long-term use of corticosteroids. There is conflicting evidence for living in a rural location, high blood pressure, diabetes and smoking. Early detection of people at risk of developing glaucoma can be initiated using our risk factor guide coupled with a comprehensive patient history. Timely future assessment and subsequent management strategies for at-risk individuals can then be effectively and efficiently actioned.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896259     DOI: 10.1071/PY10042

Source DB:  PubMed          Journal:  Aust J Prim Health        ISSN: 1448-7527            Impact factor:   1.307


  17 in total

1.  Choroidal thickness measurements in migraine patients during attack-free period.

Authors:  Emine Esra Karaca; Emine Belgin Koçer; Şengül Özdek; Hanife Tuba Akçam; Merve Bahar Ercan
Journal:  Neurol Sci       Date:  2015-08-15       Impact factor: 3.307

2.  Relationship between Sigma-1 receptor and BDNF in the visual system.

Authors:  Barbara A Mysona; Jing Zhao; Sylvia Smith; Kathryn E Bollinger
Journal:  Exp Eye Res       Date:  2017-10-12       Impact factor: 3.467

Review 3.  Inducible rodent models of glaucoma.

Authors:  Iok-Hou Pang; Abbot F Clark
Journal:  Prog Retin Eye Res       Date:  2019-09-23       Impact factor: 21.198

Review 4.  [Secondary diseases in high myopia].

Authors:  F Ziemssen; W Lagrèze; B Voykov
Journal:  Ophthalmologe       Date:  2017-01       Impact factor: 1.059

5.  Neovascular glaucoma regulation by arylsulfonyl indoline-benzamide (ASIB) through targeting NF-kB signalling pathway.

Authors:  Xiaojun Lei; Yongxia Zhao
Journal:  3 Biotech       Date:  2019-05-10       Impact factor: 2.406

6.  Lack of association between lysyl oxidase-like 1 polymorphisms and primary open angle glaucoma: a meta-analysis.

Authors:  Wen Sun; Yan Sheng; Yu Weng; Chun-Xiao Xu; Susan E I Williams; Yu-Tao Liu; Michael A Hauser; R Rand Allingham; Ming-Juan Jin; Guang-Di Chen
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

Review 7.  Myopia and diabetes mellitus as modificatory factors of glaucomatous optic neuropathy.

Authors:  Etsuo Chihara
Journal:  Jpn J Ophthalmol       Date:  2013-08-15       Impact factor: 2.447

8.  Role of BDNF/TrkB pathway in the visual system: Therapeutic implications for glaucoma.

Authors:  B A Mysona; J Zhao; K E Bollinger
Journal:  Expert Rev Ophthalmol       Date:  2016-11-23

9.  Estimating the Severity of Visual Field Damage From Retinal Nerve Fiber Layer Thickness Measurements With Artificial Intelligence.

Authors:  Xiaoqin Huang; Jian Sun; Juleke Majoor; Koenraad Arndt Vermeer; Hans Lemij; Tobias Elze; Mengyu Wang; Michael Vincent Boland; Louis Robert Pasquale; Vahid Mohammadzadeh; Kouros Nouri-Mahdavi; Chris Johnson; Siamak Yousefi
Journal:  Transl Vis Sci Technol       Date:  2021-08-02       Impact factor: 3.283

10.  Association of glutathione S transferases polymorphisms with glaucoma: a meta-analysis.

Authors:  Yibo Yu; Yu Weng; Jing Guo; Guangdi Chen; Ke Yao
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.